Navigation Links
Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
Date:9/5/2007

Organization Urges Congress to Increase Federal Funding for Deadly, Incurable Disease

SAN JOSE, Calif., Sept. 5 /PRNewswire-USNewswire/ -- The Coalition for Pulmonary Fibrosis (CPF) is launching an advertising campaign aimed at Members of Congress in support of its National IPF Awareness Week Sept. 22-29, 2007.

The campaign, which includes both print and online ads, will kick off on Sept. 6 and urge Members of Congress to take action to increase research funding for idiopathic pulmonary fibrosis (IPF), and to improve education and awareness of the disease in the medical community and general public. Prevalence of IPF has increased more than 150 percent since 2001. There is no FDA approved treatment and no cure for the disease that will claim 40,000 lives this year.

"The silence around IPF is deafening," said Mark Shreve, chief executive officer of the CPF. "This campaign represents the voices of thousands of patients who are too debilitated to travel to Capitol Hill during IPF Awareness Week and speak for themselves."

The campaign will appear in print in Congressional Quarterly's CQ Today on Sept. 6, 12, 20 and 25, and in Congressional Quarterly's online publication HealthBeat the weeks of Sept. 10 and 24.

"This campaign is a critical component of IPF Awareness Week to advance our efforts to represent the needs of this community of patients and researchers as aggressively as possible," said Shreve. "Our goal is to get the attention of Members of Congress and their staffs to gain their support for increased funding for research, education and awareness while also furthering legislation that impacts IPF patients and their families."

The ad campaign was created pro bono by Jeff Hardy, owner of Floor Eighty-Four Studio in Los Angeles, Calif. Hardy recently lost his grandfather to IPF.

To view the CPF's ads, please visit: http://www.coalitionforpf.org.

About Idiopathic Pulmonary Fibrosis (IPF)

IPF is a lung disorder characterized by a progressive scarring -- known as fibrosis -- and deterioration of the lungs, which slowly robs its victims of their ability to breathe. Approximately 128,000 Americans suffer from IPF, and there is currently no known cause or cure. An estimated 48,000 new cases are diagnosed each year. IPF is difficult to diagnose and an estimated two-thirds of patients die within five years of diagnosis.

About the Coalition for Pulmonary Fibrosis

The Coalition for Pulmonary Fibrosis (CPF) is a 501(c)(3) nonprofit organization, founded in 2001 to accelerate research efforts leading to a cure for idiopathic pulmonary fibrosis (IPF), while educating, supporting, and advocating for the community of patients, families, and medical professionals fighting this disease. The CPF funds promising research into new approaches to treat and cure pulmonary fibrosis; provides patients and families with comprehensive education materials, resources, and hope; serves as a voice for national advocacy of IPF issues; and works to improve awareness of IPF in the medical community as well as the general public. The CPF's nonprofit partners include many of the most respected medical centers and healthcare organizations in the U.S. With more than 13,000 members nationwide, the CPF is the largest nonprofit organization in the U.S. dedicated to advocating for those with pulmonary fibrosis. For more information please visit http://www.coalitionforpf.org or call (888) 222-8541.


'/>"/>
SOURCE Coalition for Pulmonary Fibrosis
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. PRIMARY PULMONARY HYPERTENSION GENE DISCOVERED
2. Long travel increase pulmonary embolism
3. CT Pulmonary Angiography Scan More Effective In Detecting Dangerous Blood Clots In The Legs
4. FDA Approves Remodulin for Pulmonary Hypertension
5. Antipsychotic Drug Linked to Pulmonary Embolism
6. Treating Pulmonary Arterial Hypertension In Children With Viagra
7. Pulmonary rehabilitation program effective for chronic obstructive pulmonary disease
8. People Suffering From Chronic Pulmonary Disease To Get Relief From Harmonica
9. Risk Factors Can Identify Pulmonary Embolism
10. Hormone Can Foretell Presence Of Potentially Fatal Pulmonary Hypertension
11. Malfunction Of Key Growth Factor Increases Mortality Rate From Pulmonary Fibrosis In Blacks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, affiliated ... Weintraub as a prominent plastic surgeon and the network’s newest partner. , ... most handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Ill. , June 23, 2016  In a startling report ... are failing their residents by lacking a comprehensive, proven plan to ... a definitive ranking of how states are tackling the worst ... to only four states – Kentucky , ... Vermont . Of the 28 failing states, three ...
Breaking Medicine Technology: